Table 2.
Univariate analysis for overall survival, progression-free survival, lymphoma-specific survival, and time to progression in the training set
| Variable | OS
|
PFS
|
LSS
|
TTP
|
||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age >45 years | 1.125 (0.515–2.812) | 0.8 | 1.348 (0.705–2.845) | 0.4 | 1.120 (0.483–3.043) | 0.7 | 1.697 (0.806–4.157) | 0.2 |
| ALC–DX ≥600 cells/μL | 0.372 (0.180–0.742) | <0.005 | 0.587 (0.339–0.917) | <0.04 | 0.330 (0.146–0.702) | <0.004 | 0.610 (0.336–0.807) | <0.04 |
| Albumin ≥4 g/dL | 0.235 (0.100–0.509) | <0.0002 | 0.515 (0.290–0.904) | <0.02 | 0.260 (0.101–0.598) | <0.001 | 0.505 (0.269–0.934) | <0.03 |
| Hemoglobin <10.5 g/dL | 2.312 (1.072–4.712) | <0.03 | 2.113 (1.151–3.736) | <0.02 | 2.058 (0.884–4.437) | 0.1 | 1.910 (0.283–1.019) | 0.06 |
| Male | 1.341 (0.674–2.704) | 0.4 | 1.341 (0.674–2.704) | 0.4 | 1.154 (0.545–2.441) | 0.7 | 1.210 (0.668–2.201) | 0.5 |
| WBC >15×109/L | 1.048 (0.440–3.091) | 0.9 | 1.550 (0.733–2.973) | 0.2 | 1.092 (0.421–3.721) | 0.7 | 1.513 (0.652–3.096) | 0.3 |
| Stage IV | 1.121 (0.525–2.667) | 0.8 | 1.353 (0.727–2.410) | 0.3 | 1.131 (0.504–2.876) | 0.8 | 1.478 (0.770–2.721) | 0.2 |
| IPS ≥3 | 2.224 (1.104–4.418) | <0.02 | 1.597 (1.108–2.771) | <0.03 | 1.973 (1.114–4.156) | <0.04 | 1.293 (1.075–2.375) | <0.04 |
| CR prior to APHSCT | 0.239 (0.039–0.791) | <0.01 | 0.430 (0.165–0.932) | <0.03 | 0.133 (0.010–0.622) | <0.006 | 0.411 (0.142–0.951) | <0.04 |
| A-LMR ≥1 | 0.145 (0.058–0.318) | <0.0001 | 0.177 (0.094–0.319) | <0.0001 | 0.065 (0.015–0.186) | <0.0001 | 0.119 (0.053–0.238) | <0.0001 |
| Infused CD34 | 1.009 (0.883–1.138) | 0.9 | 1.039 (0.936–1.145) | 0.5 | 1.046 (0.914–1.181) | 0.5 | 1.067 (0.958–1.177) | 0.2 |
Abbreviations: ALC-DX, absolute lymphocyte count at diagnosis; A-LMR, autograft lymphocyte/monocyte ratio; APHSCT, autologous peripheral hematopoietic stem cell transplantation; CI, confidence interval; CR, complete response; HR, hazard ratio; IPS, International Prognostic Score; LSS, lymphoma-specific survival; OS, overall survival; PFS, progression-free survival; TTP, time to progression; WBC, white blood cell count.